Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Felipe Furiati, Senior Director, External Supply Operations at Grünenthal. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Felipe, covering: Felipe currently works in External Supply Operations at Grünenthal, a mid-sized pharma organization with a vision of a world free of pain. He is an experienced professional in pharma strategy and operations, with a focus on external supply chain management across both pre launch and commercial products. Originally from Brazil, Felipe has lived in Ireland and the United States, and is now based in Italy. His experience in the pharmaceutical industry is complemented by time in management consulting, where he gained exposure to a range of sectors including CPG and healthcare services. Outside of work, Felipe is a mid of the pack endurance triathlete and enjoys spending time outdoors. Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tim Dietlin, Chief Executive Officer of ELIQUENT Life Science. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering: ELIQUENT As Chief Executive Officer of ELIQUENT Life Sciences, Tim Dietlin steers the company’s global priorities and strategic growth. His leadership guides ELIQUENT’s team of unmatched regulatory experts and clears the path to better health. Tim leads ELIQUENT’s global business with a focus on bringing clarity to regulatory complexity. His strategic direction leverages ELIQUENT’s combined capabilities and collective expertise to provide integrated solutions that bridge the spectrum of global regulatory challenges. Under his leadership, ELIQUENT’s platform of comprehensive solutions deliver a full-service engagement that global life sciences innovators need to gain and maintain market authorization for their products. With more than 25 years of leadership experience, Tim empowers the ELIQUENT team to redefine regulatory excellence and provide continued value to clients. Prior to joining ELIQUENT, Tim served in leadership roles with premier firms advising and serving the life sciences industry, including Campbell Alliance, IBM and Heidrick & Struggles. Tim holds a BA from Loyola University Chicago, an MBA from DePaul University, and sits on the board of the Chicago chapter of the Juvenile Diabetes Research Foundation (JDRF). Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sean Werner, Chief Technology Officer at BioLife Solutions, Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sean, covering: BioLife Sean Werner is the Chief Technology Officer at BioLife Solutions, a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. BioLife acquired Sexton Biotechnologies in 2021 where Sean was President of the company known for providing processing and handling solutions for the CGT industry. Sean received his PhD from Purdue University in Biology followed by post-doctoral positions at the Indiana University School of Medicine and Eli Lilly. Sean has previous experience filling various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. In his 23 years working in the life science industry, he has guided regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools and successful initiation of multi-national cell therapy clinical studies. Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alessandro Maselli, President and Chief Executive Officer at Catalent and Franco Negron is the Chief Executive Officer at Simtra BioPharma Solutions. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his esteemed guests during a live fireside chat at the DCAT Morgan Stanley CDMO CEO Dinner. Alessandro Maselli is the President and Chief Executive Officer of Catalent, having assumed the CEO role in July 2022 after serving as the company’s President and Chief Operating Officer since February 2019. He has been with Catalent since 2010 and has played a central role in shaping the company into one of the world’s leading contract development and manufacturing organizations serving pharmaceutical, biotechnology, and consumer health customers globally. Alessandro joined Catalent as Director of Operations at the company’s pharmaceutical, nutrition, and cosmetics facility in Italy. Over the course of more than a decade, he progressed through a series of increasingly senior leadership roles, including General Manager of the Zydis® operations in Swindon, U.K., Vice President of Operations for Europe within the Drug Delivery Solutions business, and Senior Vice President of Global Operations. In these roles, he oversaw multi-site global manufacturing networks, large-scale capacity expansions, and complex technology platforms across oral solid dose, biologics, and advanced delivery modalities. As Chief Executive Officer, Alessandro led Catalent through the COVID-19 pandemic, during which the company played a critical role in the global response by supporting vaccine and therapeutic manufacturing at unprecedented scale. More recently, he has overseen Catalent’s transition to private ownership following its $16.5 billion acquisition by Novo Holdings, positioning the company for long-term investment and growth as a privately held global CDMO. Prior to joining Catalent, Mr. Maselli held a range of operational and business leadership roles at ABB Group, Alstom, and SGS, gaining extensive experience in industrial automation, engineering, and large-scale manufacturing operations. He began his career as an automation systems engineer in the food industry. In addition to his executive role, Alessandro serves on the Board of Directors of Graphic Packaging Holding Company, to which he was appointed in May 2025. He holds bachelor’s and master’s degrees in electronic engineering from the University of Rome and is a native of Italy. Franco Negron is the Chief Executive Officer of Simtra BioPharma Solutions, a leading sterile injectable contract development and manufacturing organization formed following the divestiture of Baxter International’s BioPharma Solutions business. He was appointed CEO in 2023 by Advent International and Warburg Pincus to lead the business as an independent, private-equity-backed CDMO focused on clinical-to-commercial parenteral manufacturing. Franco is an industry veteran with nearly 30 years of pharmaceutical and biopharmaceutical experience, bringing deep expertise across sterile manufacturing, commercial operations, and global supply chain leadership. Prior to joining Simtra, he served as Chief Executive Officer of ApiJect Systems America, a medical technology company focused on advanced drug-delivery and injection systems. Earlier in his career, he held senior executive roles at Thermo Fisher Scientific, where he served as President of Commercial Operations, and at Patheon Pharmaceuticals, where he was President of Development and Commercial Operations, North America, playing a key role in scaling Patheon’s CDMO platform prior to its $7.2 billion acquisition by Thermo Fisher in 2017. Franco has also held leadership positions at several major pharmaceutical companies, including Vice President of Manufacturing and Supply at Valeant Pharmaceuticals,...

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with: Jake BehrmanDirk LangeHanns-Christian MahlerJ.D. MowerySarah Stevens Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from DCAT 2026. The event was hosted by Lead Candidate and sponsored by 3i private equity... and Molecule to Market, Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with: Jake BehrmanDirk LangeHanns-Christian MahlerJ.D. MowerySarah Stevens Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from DCAT 2026. The event was hosted by Lead Candidate and sponsored by 3i private equity... and Molecule to Market, Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Greg Plunkett, Founder and CEO of Accelagen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Greg, covering: Accelagen Greg Plunkett is the Founder and CEO of Accelagen, a full service regulatory affairs and clinical development CRO headquartered in Melbourne, Australia. His career spans almost 30 years across both big and small pharma and biotech organisations before founding Accelagen in 2010. He has supported local and international companies in developing new technologies from discovery through to commercialisation. Greg leads a highly experienced team across Australia, New Zealand and the United States, united by a mission to make a meaningful difference to the future of human health. He holds a Masters of Medical Science from the University of New South Wales and postgraduate business qualifications. Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Joerg Ahlgrimm, CEO SK pharmteco. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Joerg, covering: Joerg Ahlgrimm is a global operations and supply chain executive with more than 25 years of leadership experience across the biotech, pharmaceutical, vaccines, and medical device industries. As CEO of SK pharmteco, he leads the company’s strategic growth and operational excellence across its global manufacturing network. Prior to SK pharmteco, Joerg served as Head of Global Operations, Pharma and Biotech at Lonza AG, where he oversaw 37 sites worldwide. Earlier, he led the manufacturing network for Baxter Bioscience/Baxalta, managing a broad global footprint and extensive CMO operations. Driven by a passion for advancing patient care, Joerg is recognized for building high-performing teams and navigating complex global supply chains. He was recently appointed to the inaugural Strategic Advisory Board of BioPhorum, joining senior industry leaders to help shape the future of pharmaceutical manufacturing and supply chain resilience. Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring the overlooked trends for 2026. Nick FortinAnkit GuptaEric EdwardsDirk T. LangeKaan-Fabian KekecJ.D. MoweryMatthew BioBill VincentPhilip MacnabbChristiane BardroffJason AndersonAdam SiebertStephen DillyElisabath StampaJon AlberdiDerek HenneckeBruce Thompson Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Banks Bourne, Founder & Chief Executive Officer at Bourne Partners. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Banks, covering: Bourne Partners As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners. He and the firm have been party to more than $10 billion of transactions in the pharmaceutical (“pharma”), pharma services, and consumer healthcare sectors. Banks is also the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization, and clinical trials services to patients and partners in more than 100 countries. For almost 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jump started his interest in the healthcare sector. Since then, he has invested in more than 200 private companies / assets. While Banks has derived great satisfaction by offering focused advisory services to, and investing in, pharma, healthcare, and consumer-oriented companies that need strategic and operational insights, he is even more gratified knowing that his work has helped companies to improve the health and well-being of patients across the world. Banks is passionate about providing healthcare, and specifically pharmaceuticals, to less fortunate patients, as demonstrated by supporting The Max Foundation, Partners in Health, The Bourne Foundation, The Levine Children’s Hospital, and other non-profit organizations. He received a B.A. degree in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO). Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Julian Casciano, President & CEO at eMAX Health Systems. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julian, covering: As Chairman and Chief Executive Officer, Julian leads eMAX Health’s mission to modernize market access and patient services for pharmaceutical and biotech innovators. With a background in technology enabled pharmaceutical services, commercialization strategy, patient services, and entrepreneurship, he has built the organisation into a trusted partner for navigating the complexity of rapidly evolving medical and commercial programs. Most recently, Julian spearheaded the launch of MAVA®, a proprietary digital platform delivering rapid stakeholder insights and pricing guidance powered by real time data and AI. He also architected eMAX Health’s proprietary patient services case management system, HealthPACER®. Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring two simple questions that reveal what’s really happening inside the building: What’s the biggest internal business challenge for the year ahead? And what’s the biggest opportunity inside their business in 2026? Your host, Raman Sehgal, brings together a punchy set of operator insights spanning commercial readiness, capacity decisions, flawless execution, commercial excellence, and the shift toward deeper partnerships and integrated models. Show features insights from: Ankit GuptaNick FortinEric EdwardsJason AndersonDirk T. LangePhilip MacnabbMatthew BioBruce ThompsonBill VincentDerek HenneckeStephen DillyElisabeth StampaChristiane BardroffKaan-Fabian KekecIan TzengAdam SiebertJ.D. MoweryJon AlberdiPeter Belden Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Pep Gubau, CEO, CTO & Co-Founder at Aizon. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pep, covering: Aizon Pep Gubau is the CEO and co-founder of Aizon, and a seasoned tech entrepreneur with four decades of experience and two previously successful companies. He has a unique background as an economist with a foundation in engineering, and he holds several international patents in encryption, data transmission, storage, and processing for regulated cloud environments. Pep is also a frequent speaker on the impact of Big Data, Machine Learning, and other Artificial Intelligence technologies, sharing insights into how these innovations are transforming regulated industries. Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the big headwinds for the pharmaceutical and biotechnology space for 2026. Show features: Christiane BardroffPhilip MacnabbKaan-Fabian KekecDirk T. LangeBill VincentDerek HenneckeMatthew BioStephen DillyBill HumphriesElisabeth StampaKerstin DolphEric EdwardsPeter DeYoungIan TzengAdam SiebertJ.D. MoweryPeter BeldenNick Fortin Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with three senior leaders that attended The JPM's Annual Healthcare Conference 2026: Chris GarabedianXontogenyPXV FundDean McAlisterInizio BiotechCatherine Hunterramarketing Hear from experts who have seen multiple cycles and know the difference between noise and signal.We talk real confidence levels, what actually dominated conversations in San Francisco, where capital and opportunity are genuinely moving. Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the optimism levels for the pharmaceutical and biotechnology space for 2026. Guests include: Christiane BardroffPhilip MacnabbKaan-Fabian KekecDirk T. LangeBill VincentDerek HenneckeMatthew BioBill HumphriesElisabeth StampaPhilip LeeKerstin DolphEric EdwardsPeter DeYoungIan TzengAdam SiebertJ.D. MoweryPeter Belden Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Selin Kurnaz, Co-Founder and CEO at Massive Bio, Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Selin, covering: Massive Bio’s Selin Kurnaz graduated from Boğaziçi University in Turkey, where she had a dual major in industrial engineering and mechanical engineering. She then continued her education in the United States, where she obtained two masters degrees and a doctorate in mechanical engineering at the University of Michigan. Following her education, Selin served as an executive consultant on strategy, operations, and company trading for a decade. In 2015, she co-founded Massive Bio. Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Gale, Founding Partner & Managing Director at Signet. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: SignetSignet James “Jim” Gale is the Founding Partner and Managing Director of Signet Healthcare Partners, a New York based healthcare growth equity firm specialising in pharmaceutical services, specialty pharma and medical technology. With more than thirty five years of investing and finance experience, Jim has built a deep track record backing companies involved in formulation, development, manufacturing and commercialisation across the world. At Signet, Jim has led investments across the pharma services value chain, including platforms in sterile fill finish, complex formulations, biologics development and specialty generics. His current and recent board roles include Ascendia Pharmaceutical Solutions, NorthX Biologics, RK Pharma, Bionpharma, Chr Olesen Synthesis, Pharma Nobis, Juno Pharmaceuticals and Lee’s Pharmaceutical. He also serves as Chairman of Bionpharma and is a director of Knight Therapeutics. Jim holds an MBA from the University of Chicago Booth School of Business. Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

As we draw close to the end of 2025, our host Raman Sehgal talks about the top 5 episodes of the year. Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Thomas Dobmeyer, medical, entrepreneur and investor at ekwithree. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering: Dr. Thomas Dobmeyer is a physician, researcher, and entrepreneur currently serving as a partner at ekwithree GmbH, a growth investment firm specializing in technology-driven B2B service providers. In this role, Thomas plays a key part in driving the organizational success of ekwithree and its diverse portfolio of companies. With over two decades of extensive experience in the pharmaceutical and medical technology industries, Thomas was founder and CEO of PharmaLex GmbH. There, he spearheaded the transformation of a startup consulting boutique into a globally recognized unicorn company operating in 40 countries with 3,500 employees. His strategic expertise was instrumental in shaping and executing the company’s business strategies, overseeing leadership team formation, advising on strategic matters, and ensuring the implementation of robust business plans to achieve corporate objectives. Under his leadership, PharmaLex successfully completed nearly 40 mergers and acquisitions, significantly expanding its global business model and footprint. Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!